Implantica AG (publ.) will hold its Capital Markets Day on September 9, 2026, from 14:00 to 16:30 CEST at Sergelkonferensen in Stockholm. The event will focus on plans following recent FDA approval of RefluxStop®, including the U.S. market-launch strategy and growth opportunity in a market where an estimated 78 million people suffer from acid reflux. Management, RefluxStop® surgeons and patients will discuss clinical and patient perspectives, while investors and media can also attend through a live webcast.